Healthcare System Resilience and Sustainability: Lessons Learned for HEOR in Times of Crisis
COVID-19 has brought the strengths and weaknesses of health systems around the world into sharp relief. We have seen health systems respond more quickly and more cohesively than many thought possible—new hospitals were built in record time, countries pulled together to create PPE stockpiles, and the spirit of collaboration in the pharmaceutical sector to bring a vaccine to market has been positive and encouraging. What have we learned about resilience, sustainability, and the ability to respond effectively during the crisis? And how can HEOR experts help build resilient healthcare systems, on both human and fiscal levels going forward? This session will consider what useful lessons we have learned from the SARS-CoV-2 pandemic so far, and what health systems need from the HEOR community to help build resilience and sustainability in healthcare systems.
Stepping Up to the Challenge: How Novel Collaborations and New Players are Reshaping the HEOR Landscape
New and interesting HEOR collaborations are emerging to address the extraordinary challenges many countries face today with their health systems and that also focus on health technology innovation. Traditional players—such as regulators, payers, and providers—are seeking innovative partnerships that leverage new data sources. New players—including major technology companies, digital health startups, and engineers with machine learning backgrounds—are utilizing strategic alliances to "reinvent" HEOR. This session will bring together thought leaders from government, payers, technology, and academia who are doing things differently in healthcare to share examples and thoughts on how this may reshape the world of HEOR.
The COVID-19 pandemic has highlighted major methodological issues regarding the assessment of value, the trade-offs involved, and the approaches to estimating the public health and economic consequences. In our field, we have been used to focusing on these aspects with an average patient and single product as the unit of analysis: we estimate how many QALYs a patient will gain with each comparator and how much cost that will generate, to compute an ICER as an indirect measure of the trade-off. But, as the pandemic shows us, the decisions made when facing such a threat are at the population level. The public health concern is to decrease transmission, sustain hospital capacity, reduce mortality, by imposing various measures on the population; the trade-offs include increased unemployment, diminished GDP, substantial rescue packages, and massive damage to some industries. Today, much as it was 50 years ago in our field, these expanded trade-offs are made informally by various authorities, but perhaps we need newer methods of “public health economics” to help decision makers with quantitative understanding of the consequences. This session will explore an expanded perspective on HEOR scope and application and examine, in turn, possible lessons for our consideration of value and its assessment.